OncoMatch/Clinical Trials/NCT07354022
A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
Is NCT07354022 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including HRS-8080 Tablet ; Dalpiciclib Isethionate and Fulvestrant for locally advanced or metastatic breast cancer.
Treatment: HRS-8080 Tablet ; Dalpiciclib Isethionate · Fulvestrant — The study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced/metastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
locally advanced or metastatic breast cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: adjuvant endocrine therapy — adjuvant
Patients with prior adjuvant endocrine resistance following curative-intent surgery
Cannot have received: fulvestrant or other novel SERMs (fulvestrant)
Exception: excluding tamoxifen and toremifene
Patients who have previously received fulvestrant or other novel SERMs (excluding tamoxifen and toremifene)
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify